Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease.

MM, Hudson; M, Krasin; MP, Link; SS, Donaldson; C, Billups; TE, Merchant; L, Kun; AL, Billet; S, Kaste; NJ, Tarbell; S, Howard; AM, Friedmann; CA, Hurwitz; JA, Young; KC, Marcus; S, Rai; T, Cowan; HJ, Weinstein

doi:10.1200/jco.2004.02.139

Public

Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease.

Shared by NobleBlocks on Nov 1, 2004 • 12:00 AM UTC

Authors:

Hudson MM

Krasin M

Link MP

Abstract

<h4>Purpose</h4>To evaluate the efficacy of vinblastine, doxorubicin, methotrexate, and prednisone (VAMP) and cyclophosphamide, vincristine, and procarbazine (COP) chemotherapy and response-based, involved-field radiation, a combined-modality regimen that limits doses of alkylating agents, anthracyc...

Discussions